Definition
Urocanic aciduria is a rare inherited metabolic disorder characterized by the accumulation and excretion of elevated concentrations of urocanic acid in the urine. The condition results from a deficiency of the enzyme urocanase (also called urocanate hydratase), which catalyzes the conversion of urocanic acid to 4‑imidazolone‑5‑propionate in the histidine degradation pathway.
Overview
Urocanic aciduria belongs to the group of inborn errors of metabolism affecting amino‑acid catabolism. The disorder is typically inherited in an autosomal recessive manner, requiring pathogenic variants in both copies of the UROC gene that encodes urocanase. Biochemically, the enzymatic block leads to the buildup of urocanic acid, which is subsequently excreted in the urine and can be detected by qualitative or quantitative organic‑acid analysis (e.g., gas chromatography‑mass spectrometry).
Most individuals identified with urocanic aciduria are clinically asymptomatic and the condition is often discovered incidentally during newborn screening or metabolic investigations for unrelated reasons. A limited number of case reports have described mild neurological manifestations, such as developmental delay or seizures, but a causal relationship has not been definitively established. There is currently no specific therapy; management is generally supportive and may include dietary counseling to limit excess histidine intake, although the benefit of such measures remains uncertain.
Etymology/Origin
The term combines “urocanic acid,” the metabolic intermediate that accumulates, with the suffix “‑uria,” derived from the Greek ouron (urine) and ‑ia denoting a condition. Thus, “urocanic aciduria” literally means “the presence of urocanic acid in the urine.”
Characteristics
| Feature | Description |
|---|---|
| Biochemical defect | Deficiency of urocanase (urocanate hydratase) in the histidine catabolic pathway. |
| Genetic basis | Autosomal recessive pathogenic variants in the UROC gene. |
| Laboratory findings | Markedly elevated urinary urocanic acid; normal plasma histidine and other metabolic intermediates. |
| Clinical presentation | Frequently asymptomatic; occasional reports of mild neuro‑developmental issues. |
| Diagnostic methods | Urine organic‑acid profiling, enzyme assay (research settings), molecular genetic testing for UROC variants. |
| Treatment | No disease‑specific therapy; dietary histidine restriction is sometimes considered but lacks robust evidence. |
| Prognosis | Generally favorable in asymptomatic individuals; long‑term outcomes for symptomatic cases are not well documented. |
Related Topics
- Histidine metabolism
- Urocanase deficiency (alternative name)
- Inborn errors of metabolism
- Organic acidurias
- Newborn metabolic screening
- UROC gene and associated variants
Note: Information about clinical variability and therapeutic interventions is derived from limited case reports; comprehensive natural‑history data are not available.